MindWalk Holdings Corp. reported its financial results for the first fiscal quarter of 2026, ended July 31, 2025. The company achieved record quarterly revenue of $7.6 million, marking a 45% increase year-over-year. Revenue from continuing operations was $3.2 million, representing a 28% growth, while discontinued operations, primarily from the Netherlands operations divested in early Q2, contributed $4.4 million. The gross profit for the quarter was $4.0 million, up from $2.4 million in the previous year, with a gross margin expansion to 53%. Continued operations contributed $1.5 million at a 48% margin, whereas discontinued operations contributed $2.5 million at a 56% margin. MindWalk's net loss improved to $3.0 million from $4.0 million in the prior year. The company's cash balance at the end of the quarter was $5.0 million, augmented by $16.1 million in net proceeds from the divestiture of its Netherlands operations. Significant corporate developments included the rebranding of the company to MindWalk, integrating ImmunoPrecise Antibodies, BioStrand, and Talem under a unified identity. The divestiture of its Netherlands operations is intended to sharpen the company's focus on high-growth, AI-driven initiatives. Furthermore, the company advanced its dengue vaccine program into preclinical manufacturing and expanded validation of its LensAI platform, which aims to de-risk biologics development by predicting Anti-Drug-Antibody risk, thereby assisting partners in accelerating their programs and reducing costly late-stage failures.